Collegium Pharma (COLL) Provides 2024 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Collegium Provides 2024 Financial Guidance
January 3, 2024 8:00 AM EST Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million
Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million
Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 Million
$150.0 Million Share Repurchase Program Authorized by the Board of Directors
STOUGHTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2024 full-year financial guidance and provided a business update.
2023... More
